Click Fundraise to create your own personal Global Psychedelic Dinners fundraising page, and help make psychedelic therapy a legal treatment. Don’t forget to Register to Host your own dinner so we can send you everything you need to make the most of your dinner.
This April, we invite you to gather your friends, family, and colleagues for your own Global Psychedelic Dinner. Join this team to join the worldwide community of people participating—in person and online—in the global movement to make psychedelic therapy a legal treatment.
By hosting your own Global Psychedelic Dinner, you’ll join people around the world in gathering your community, hosting an open conversation about psychedelic science and medicine, spreading the word, and raising funds for MAPS’ purchase of one kilogram of pharmaceutical grade MDMA for our Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).
The Global Psychedelic Dinners are also your chance to share your story about why you support psychedelic science and medicine. You’ll be helping reduce stigma and enhance public understanding of the risks and beneficial uses of psychedelics for science, healing, spirituality, creativity, and personal growth. Come out of the psychedelic closet and help integrate psychedelics back into mainstream culture.
What is MAPS?
Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
Since 1986, MAPS has disbursed over $26 million to scientific research and public education about the risks and benefits of psychedelics and marijuana. This April, we’re asking you to join us in celebrating our 30 years of pioneering research and honest education through the Global Psychedelic Dinners and 30th Anniversary Banquet and Celebration in Oakland, Calif. Almost all our support comes from individuals and family foundations.
MAPS has completed an international series of Phase 2 clinical trials of MDMA-assisted psychotherapy for PTSD, and is now preparing for the much larger Phase 3 trials required to obtain U.S. Food and Drug Administration (FDA) approval, starting in 2017. As long as we receive the necessary funding, we anticipate FDA approval for MDMA-assisted psychotherapy for PTSD as soon as 2021.